Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
- Registration Number
- NCT06157580
- Lead Sponsor
- Anna Stanhewicz, PhD
- Brief Summary
Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.
The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function.
In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 24
- women who had preeclampsia and women who did not have preeclampsia
- 12 weeks to 5 years postpartum
- 18-45 years old
- history of hypertension or metabolic disease before pregnancy
- history of gestational diabetes or gestational hypertension
- skin diseases
- current tobacco use
- current antihypertensive medication
- statin or other cholesterol-lowering medication
- currently pregnant or planning to become pregnant
- body mass index less than <18.5 or >30 kg/m2
- allergy to materials used during the experiment.(e.g. latex),
- known allergy to study drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description History of a preeclampsia Angiotensin II Women who had preeclampsia in their most recent pregnancy History of a preeclampsia Compound 21 Women who had preeclampsia in their most recent pregnancy History of a healthy pregnancy Compound 21 Women who had an uncomplicated pregnancy History of a healthy pregnancy Angiotensin II Women who had an uncomplicated pregnancy
- Primary Outcome Measures
Name Time Method Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry at the study visit, an average of 4 hours cutaneous vascular vasodilator responses to compound 21 perfusion in lactated Ringer's and losartan treated microdialysis sites
Change in microvascular ang II-mediated constriction response measured by laser-Doppler flowmetry at the study visit, an average of 4 hours cutaneous vascular vasoconstrictor responses to angiotensin II perfusion in lactated Ringer's and PD-123319 treated microdialysis sites
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Iowa
🇺🇸Iowa City, Iowa, United States